Abpro Holdings (ABP) Stock Overview
A biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ABP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Abpro Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.90 |
| 52 Week High | US$42.90 |
| 52 Week Low | US$3.78 |
| Beta | 0.013 |
| 1 Month Change | -32.50% |
| 3 Month Change | -30.94% |
| 1 Year Change | -90.31% |
| 3 Year Change | -98.73% |
| 5 Year Change | n/a |
| Change since IPO | -98.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.5% | -1.4% | 0.2% |
| 1Y | -90.3% | 27.9% | 16.9% |
Return vs Industry: ABP underperformed the US Biotechs industry which returned 28.4% over the past year.
Return vs Market: ABP underperformed the US Market which returned 18.7% over the past year.
Price Volatility
| ABP volatility | |
|---|---|
| ABP Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ABP's weekly volatility has decreased from 19% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 11 | Miles Suk | abpro.co |
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company’s lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration.
Abpro Holdings, Inc. Fundamentals Summary
| ABP fundamental statistics | |
|---|---|
| Market cap | US$10.57m |
| Earnings (TTM) | -US$22.04m |
| Revenue (TTM) | n/a |
Is ABP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | -US$1.52m |
| Gross Profit | US$1.52m |
| Other Expenses | US$23.56m |
| Earnings | -US$22.04m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -0.9% |
How did ABP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/14 18:49 |
| End of Day Share Price | 2026/01/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abpro Holdings, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |